Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Risperdal cases. Here at Leading Justice, we can custom-tailor your firm’s Risperdal advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of Risperdal advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that isn’t eligible for the target campaign is reviewed to determine whether it qualifies for another type of claim. By utilizing innovative approaches to target contacts specifically related to Risperdal and side effects like gynecomastia, Leading Justice will increase your firm’s Risperdal case load. If you are interested in helping victims of gynecomastia and other alleged Risperdal side effects, our vast consumer reach and direct advertising strategies give you the competitive edge and confidence to allocate your full budget, and rest easy knowing your money is being spent the best way possible.
Each and every law firm we work with at Leading Justice plays an important role in how we classify claims as qualified or not. While our experience working with plaintiff law firms allows us to recognize a great case when we see one, we will customize our Risperdal case intake specifications to the exact criteria you are seeking. So, if your firm has specific Risperdal qualifying case criteria you would like us to use, we will train our intake specialists to apply the criteria to each phone call and email they receive.
Risperdal and Gynecomastia Litigation
Risperdal is the brand name of an atypical antipsychotic drug manufactured by pharmaceutical giant Johnson & Johnson and widely prescribed for the treatment of schizophrenia and bipolar disorder. Risperdal was approved by the FDA in 1993, and in 1999, the first study identifying gynecomastia – or breast growth in boys – as a potential side effect of Risperdal treatment was published. According to researchers, use of the antispychotic medication may result in elevated levels of the hormone prolactin, which has been linked to abnormal breast growth (gynecomastia) in men, and studies show these elevated levels may persist for up to two years in Risperdal patients.
To date, Johnson & Johnson faces at least 420 lawsuits filed on behalf of Risperdal users, many of which are males who have experienced breast growth significant enough to trigger emotional and psychological problems like low self-esteem and loss of enjoyment of life. According to recent reports, Johnson & Johnson has already settled several Risperdal lawsuits involving gynecomastia and other side effects, including diabetes, heart attack, tardive dyskinesia and stroke, as well as claims that the drug company illegally promoted its antipsychotic drug for use in children and elderly patients. In the past year alone, J&J has paid billions in fines and settlements over Risperdal, and complaints involving the antipsychotic continue to mount.